The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.
Menendez criticizes the lack of oversight in the PBM market.
Share & report
More from Bob Menendez
While I applaud these engagements on global AI governance, more must be done in this area of strategic competition.
The People's Republic of China has committed a despicable campaign of genocide against the Uyghur people and has exported its suppression to target ethnic and religious minority groups and their family members globally.
The reality is that if Iran is dramatically curtailed in its flow of revenue, it has domestic consequences in terms of those who wish to see a change in their own country.
I have been advocating for that so that we have lines of communication, particularly for nonconflict issues in China.
Other voices in this conversation
